STAAR Surgical Competitors

Align Technology (NASDAQ:ALGN) and STAAR Surgical (NASDAQ:STAA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Valuation & Earnings

This table compares Align Technology and STAAR Surgical's revenue, earnings per share (EPS) and valuation.

Align Technology has higher revenue and earnings than STAAR Surgical. Align Technology is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

85.8% of Align Technology shares are held by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are held by institutional investors. 1.2% of Align Technology shares are held by company insiders. Comparatively, 3.9% of STAAR Surgical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Align Technology and STAAR Surgical, as provided by MarketBeat.com.

Align Technology currently has a consensus price target of $627.0909, indicating a potential upside of 10.16%. STAAR Surgical has a consensus price target of $68.50, indicating a potential downside of 45.09%. Given Align Technology's stronger consensus rating and higher possible upside, analysts clearly believe Align Technology is more favorable than STAAR Surgical.

Profitability

This table compares Align Technology and STAAR Surgical's net margins, return on equity and return on assets.

Risk & Volatility

Align Technology has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Summary

Align Technology beats STAAR Surgical on 11 of the 14 factors compared between the two stocks.

STAAR Surgical (NASDAQ:STAA) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Valuation & Earnings

This table compares STAAR Surgical and West Pharmaceutical Services' gross revenue, earnings per share (EPS) and valuation.

West Pharmaceutical Services has higher revenue and earnings than STAAR Surgical. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

85.4% of STAAR Surgical shares are held by institutional investors. Comparatively, 92.6% of West Pharmaceutical Services shares are held by institutional investors. 3.9% of STAAR Surgical shares are held by insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

STAAR Surgical has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for STAAR Surgical and West Pharmaceutical Services, as reported by MarketBeat.com.

STAAR Surgical presently has a consensus target price of $68.50, suggesting a potential downside of 45.09%. West Pharmaceutical Services has a consensus target price of $310.00, suggesting a potential downside of 5.66%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, analysts plainly believe West Pharmaceutical Services is more favorable than STAAR Surgical.

Profitability

This table compares STAAR Surgical and West Pharmaceutical Services' net margins, return on equity and return on assets.

Summary

West Pharmaceutical Services beats STAAR Surgical on 10 of the 14 factors compared between the two stocks.

The Cooper Companies (NYSE:COO) and STAAR Surgical (NASDAQ:STAA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Profitability

This table compares The Cooper Companies and STAAR Surgical's net margins, return on equity and return on assets.

Insider and Institutional Ownership

95.8% of The Cooper Companies shares are owned by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are owned by institutional investors. 1.4% of The Cooper Companies shares are owned by insiders. Comparatively, 3.9% of STAAR Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for The Cooper Companies and STAAR Surgical, as reported by MarketBeat.

The Cooper Companies currently has a consensus target price of $385.50, indicating a potential downside of 3.84%. STAAR Surgical has a consensus target price of $68.50, indicating a potential downside of 45.09%. Given The Cooper Companies' stronger consensus rating and higher probable upside, research analysts clearly believe The Cooper Companies is more favorable than STAAR Surgical.

Valuation & Earnings

This table compares The Cooper Companies and STAAR Surgical's gross revenue, earnings per share and valuation.

The Cooper Companies has higher revenue and earnings than STAAR Surgical. The Cooper Companies is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

The Cooper Companies has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.

Summary

The Cooper Companies beats STAAR Surgical on 10 of the 14 factors compared between the two stocks.

STAAR Surgical (NASDAQ:STAA) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for STAAR Surgical and DENTSPLY SIRONA, as provided by MarketBeat.com.

STAAR Surgical presently has a consensus target price of $68.50, suggesting a potential downside of 45.09%. DENTSPLY SIRONA has a consensus target price of $55.8182, suggesting a potential downside of 17.42%. Given DENTSPLY SIRONA's higher probable upside, analysts clearly believe DENTSPLY SIRONA is more favorable than STAAR Surgical.

Institutional & Insider Ownership

85.4% of STAAR Surgical shares are owned by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are owned by institutional investors. 3.9% of STAAR Surgical shares are owned by insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

STAAR Surgical has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Profitability

This table compares STAAR Surgical and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares STAAR Surgical and DENTSPLY SIRONA's gross revenue, earnings per share and valuation.

DENTSPLY SIRONA has higher revenue and earnings than STAAR Surgical. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

STAAR Surgical beats DENTSPLY SIRONA on 8 of the 14 factors compared between the two stocks.

Neogen (NASDAQ:NEOG) and STAAR Surgical (NASDAQ:STAA) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Profitability

This table compares Neogen and STAAR Surgical's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Neogen and STAAR Surgical's revenue, earnings per share (EPS) and valuation.

Neogen has higher revenue and earnings than STAAR Surgical. Neogen is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Neogen and STAAR Surgical, as reported by MarketBeat.com.

Neogen presently has a consensus price target of $81.50, suggesting a potential downside of 12.89%. STAAR Surgical has a consensus price target of $68.50, suggesting a potential downside of 45.09%. Given Neogen's higher probable upside, equities analysts clearly believe Neogen is more favorable than STAAR Surgical.

Volatility and Risk

Neogen has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Institutional & Insider Ownership

92.8% of Neogen shares are owned by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are owned by institutional investors. 0.9% of Neogen shares are owned by company insiders. Comparatively, 3.9% of STAAR Surgical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Quidel (NASDAQ:QDEL) and STAAR Surgical (NASDAQ:STAA) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Institutional and Insider Ownership

84.0% of Quidel shares are owned by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are owned by institutional investors. 14.1% of Quidel shares are owned by insiders. Comparatively, 3.9% of STAAR Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Quidel and STAAR Surgical, as reported by MarketBeat.com.

Quidel currently has a consensus price target of $189.00, suggesting a potential upside of 68.00%. STAAR Surgical has a consensus price target of $68.50, suggesting a potential downside of 45.09%. Given Quidel's higher probable upside, research analysts plainly believe Quidel is more favorable than STAAR Surgical.

Profitability

This table compares Quidel and STAAR Surgical's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Quidel and STAAR Surgical's revenue, earnings per share and valuation.

Quidel has higher revenue and earnings than STAAR Surgical. Quidel is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Quidel has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Summary

Quidel beats STAAR Surgical on 8 of the 12 factors compared between the two stocks.